Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome

Molecular Genetics and Metabolism Reports

Volumn 10, Issue , 2017, Pages 67-74

  Nakamura, Sachie ^a   Osaka, Hitoshi ^a   Muramatsu, Shin ichi ^a,d   Takino, Naomi ^a   Ito, Mika ^a   Aoki, Shiho ^a   Jimbo, Eriko F ^a   Shimazaki, Kuniko ^a   Onaka, Tatsushi ^a   Ohtsuki, Sumio ^b   Terasaki, Tetsuya ^c   Yamagata, Takanori ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adeno associated virus (AAV); Gene therapy; Glucose transporter I deficiency syndrome (GLUT1DS); GLUT1; SLC2A1

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; GLUCOSE; GLUCOSE TRANSPORTER 1; SYNAPSIN I;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; AUTOSOMAL DOMINANT DISORDER; BRAIN CORTEX; CELL CULTURE; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENDOTHELIUM CELL; FOOTPRINT TEST; GLUCOSE TRANSPORTER 1 DEFICIENCY SYNDROME; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOTOR FUNCTION TEST; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; ROTAROD TEST; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 85009291829     PISSN: None     EISSN: 22144269     Source Type: Journal    
DOI: 10.1016/j.ymgmr.2016.12.008     Document Type: Article

References (30)

1. [1] Maher, F., Vannucci, S.J., Simpson, I.A., Glucose transporter proteins in brain. FASEB J. 8 (1994), 1003–1011.
2. [2] Vannucci, S.J., Maher, F., Simpson, I.A., Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 21 (1997), 2–21.
3. [3] Simpson, I.A., Carruthers, A., Vannucci, S.J., Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J. Cereb. Blood Flow Metab. 27 (2007), 1766–1791.
4. [4] Choeiri, C., Staines, W., Messier, C., Immunohistochemical localization and quantification of glucose transporters in the mouse brain. Neuroscience 111 (2002), 19–34.
5. [5] Hildebrand, M.S., Damiano, J.A., Mullen, S.A., Bellows, S.T., Oliver, K.L., Dahl, H.H., Scheffer, I.E., Berkovic, S.F., Glucose metabolism transporters and epilepsy: only GLUT1 has an established role. Epilepsia 55 (2014), e18–e21.
6. [6] Klepper, J., Leiendecker, B., GLUT1 deficiency syndrome—2007 update. Dev. Med. Child Neurol. 49 (2007), 707–716.
7. [7] De Giorgis, V., Veggiotti, P., GLUT1 deficiency syndrome 2013: current state of the art. Seizure 22 (2013), 803–811.
8. [8] Ito, Y., Takahashi, S., Kagitani-Shimono, K., Natsume, J., Yanagihara, K., Fujii, T., Oguni, H., Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan. Brain Dev. 37 (2015), 780–789.
9. [9] Leen, W.G., Wevers, R.A., Kamsteeg, E.J., Scheffer, H., Verbeek, M.M., Willemsen, M.A., Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. JAMA. Neurol. 70 (2013), 1440–1444.
10. [10] Leen, W.G., Taher, M., Verbeek, M.M., Kamsteeg, E.J., van de Warrenburg, B.P., Willemsen, M.A., GLUT1 deficiency syndrome into adulthood: a follow-up study. J. Neurol. 261 (2014), 589–599.
11. [11] Klepper, J., Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia 49:Suppl. 8 (2008), 46–49.
12. [12] Fujii, T., Ito, Y., Takahashi, S., Shimono, K., Natsume, J., Yanagihara, K., Oguni, H., Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan: a nationwide survey. Brain Dev. 38 (2016), 628–637.
13. [13] Ito, Y., Oguni, H., Ito, S., Oguni, M., Osawa, M., A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndrome. Dev. Med. Child Neurol. 53 (2011), 658–663.
14. [14] Kwiterovich, P.O. Jr., Vining, E.P., Pyzik, P., Skolasky, R. Jr., Freeman, J.M., Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 290 (2003), 912–920.
15. [15] Mochel, F., Hainque, E., Gras, D., Adanyeguh, I.M., Caillet, S., Heron, B., Roubertie, A., Kaphan, E., Valabregue, R., Rinaldi, D., Vuillaumier, S., Schiffmann, R., Ottolenghi, C., Hogrel, J.Y., Servais, L., Roze, E., Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J. Neurol. Neurosurg. Psychiatry 87 (2016), 550–553.
16. [16] Hwu, W.L., Muramatsu, S., Tseng, S.H., Tzen, K.Y., Lee, N.C., Chien, Y.H., Snyder, R.O., Byrne, B.J., Tai, C.H., Wu, R.M., Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med., 4, 2012, 134ra161.
17. [17] Fu, H., Cataldi, M.P., Ware, T.A., Zaraspe, K., Meadows, A.S., Murrey, D.A., McCarty, D.M., Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery. Mol. Ther. Methods Clin. Dev., 3, 2016, 16036.
18. [18] Ohtsuki, S., Kikkawa, T., Hori, S., Terasaki, T., Modulation and compensation of the mRNA expression of energy related transporters in the brain of glucose transporter 1-deficient mice. Biol. Pharm. Bull. 29 (2006), 1587–1591.
19. [19] Wang, D., Pascual, J.M., Yang, H., Engelstad, K., Mao, X., Cheng, J., Yoo, J., Noebels, J.L., De Vivo, D.C., A mouse model for Glut-1 haploinsufficiency. Hum. Mol. Genet. 15 (2006), 1169–1179.
20. [20] Iida, A., Takino, N., Miyauchi, H., Shimazaki, K., Muramatsu, S., Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. Biomed. Res. Int., 2013, 2013, 974819.
21. [21] DeMattos, R.B., Bales, K.R., Parsadanian, M., O'Dell, M.A., Foss, E.M., Paul, S.M., Holtzman, D.M., Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81 (2002), 229–236.
22. [22] Nakamura, S., Osaka, H., Muramatsu, S., Aoki, S., Jimbo, E.F., Yamagata, T., Mutational and functional analysis of glucose transporter I deficiency syndrome. Mol. Genet. Metab. 116 (2015), 157–162.
23. [23] Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., Kaspar, B.K., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27 (2009), 59–65.
24. [24] Iwata, N., Sekiguchi, M., Hattori, Y., Takahashi, A., Asai, M., Ji, B., Higuchi, M., Staufenbiel, M., Muramatsu, S., Saido, T.C., Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci. Rep., 3, 2013, 1472.
25. [25] Yamashita, T., Chai, H.L., Teramoto, S., Tsuji, S., Shimazaki, K., Muramatsu, S., Kwak, S., Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO. Mol. Med. 5 (2013), 1710–1719.
26. [26] Gladden, L.B., Lactate metabolism: a new paradigm for the third millennium. J. Physiol. 558 (2004), 5–30.
27. [27] Stuart, C.A., Ross, I.R., Howell, M.E., McCurry, M.P., Wood, T.G., Ceci, J.D., Kennel, S.J., Wall, J., Brain glucose transporter (Glut3) haploinsufficiency does not impair mouse brain glucose uptake. Brain Res. 1384 (2011), 15–22.
28. [28] Samaranch, L., Salegio, E.A., San Sebastian, W., Kells, A.P., Foust, K.D., Bringas, J.R., Lamarre, C., Forsayeth, J., Kaspar, B.K., Bankiewicz, K.S., Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23 (2012), 382–389.
29. [29] Samaranch, L., Salegio, E.A., San Sebastian, W., Kells, A.P., Bringas, J.R., Forsayeth, J., Bankiewicz, K.S., Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24 (2013), 526–532.
30. [30] Huda, F., Konno, A., Matsuzaki, Y., Goenawan, H., Miyake, K., Shimada, T., Hirai, H., Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model. Mol. Ther. Methods Clin. Dev., 1, 2014, 14032.